Exosome Development and Manufacturing Services Market Size is valued at USD 17.2 Bn in 2023 and is predicted to reach USD 62.8 Bn by the year 2031 at an 17.9% CAGR during the forecast period for 2024-2031.
Exosomes, which range in diameter from 30 to 150 nm and are membrane-bound extracellular vesicles, are secreted into the extracellular environment by a wide variety of cell types. They develop inside the multivesicular bodies (MVBs) that contain cells and are expelled when the MVBs merge with the plasma membrane. Exosomes are essential for the transfer of biomolecules between cells, including lipids, proteins, RNA, and DNA. This allows for intercellular communication. Exosomes are being studied as biomarkers for diagnosing diseases, as their composition reflects the state of their cells of origin. Their capacity to target certain cells and their biocompatibility make them ideal candidates for use as natural delivery systems for medications, RNA treatments, and gene editing instruments. Exosomes generated from stem cells are being researched in regenerative medicine for their ability to aid in tissue regeneration and repair.
The rising prevalence of chronic disease and conditions associated with aging populations is fueling demand for innovative therapeutic solutions, including exosome-based treatment. The need for novel therapies to address them is rising. The use of exosome-based technologies in cancer research and treatment has increased dramatically as a result of this need. In cancer diagnosis, the idea of "liquid biopsy," which entails examining biomarkers in physiological fluids like blood, urine, or saliva, is becoming increasingly popular. Exosomes are excellent candidates for liquid biopsy techniques because they are stable molecular information carriers. Exosome biomarkers are being investigated by researchers as a means of tracking the course of disease, gauging the effectiveness of treatment, and identifying minimally residual disease.
Competitive Landscape
Some of the Major Key Players in the Exosome Development and Manufacturing Services Market are
- 101 Bio
- 10x Genomics
- Aegle Therapeutics
- Aethlon Medical
- AMSBIO
- Anjarium Biosciences
- Aruna Bio
- Bio-Techne
- Capricor Therapeutics
- CD Bioparticles
- Cell Guidance Systems
- Cellular Biomedicine Group (CBMG)
- Clara Biotech
- Codiak BioSciences
- Creative Biolabs
- Creative Biostructure
- Creative Bioarray
- Creative Proteomics
- Curexsys
- Direct Biologics
- EV Therapeutics
- EVerZom
- Evox Therapeutics
- ExoCoBio
- Exogenus Therapeutics
- Exosome Diagnostics
- Exosome Plus
- Exosomics
- Exopharm
- Exosome Sciences
- Exosome Diagnostics
- Exosome Plus
- Izon Science
- Kimera Labs
- Lonza
- MDimune
- Miltenyi Biotec
- NanoView Biosciences
- Norgen Biotek
- NurExone Biologic
- System Biosciences (SBI)
- Takeda
- Thermo Fisher Scientific
- Vesigen Therapeutics
- VivaZome Therapeutics
- XOStem
Market Segmentation:
The Exosome Development and Manufacturing Services Market is segmented based on types of service(s) offered, scale of operation, and scalability. The Types of Service(s) Offered segments isolated exosomes, exosome characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control. The Scale of Operation segments discovery / research, pre-clinical, clinical or commercialized. The scalability segment comprises small, mid-sized or large.
The Target Delivery Segment Dominate the Market
Based on the types of service(s) offered, the exosome development and manufacturing services market is segmented into isolated exosomes, exosome characterization, purification, chromatography, engineering, targeted delivery, diagnostic biomarker, and quality control. The target delivery segment is expected to drive the market. The application of exosomes in targeted delivery systems, especially in drug delivery, is a major driver. Targeted delivery through exosomes represents a cutting-edge approach in the field of drug delivery. Exosomes, naturally occurring vesicles, are inherently biocompatible and capable of transporting a broad spectrum of therapeutic molecules. Exosomes can be engineered to deliver therapeutic agents to specific cells or tissues, improving treatment effectiveness and lowering side effects.
The Discovery / Research Segment is Expected to Drive the Exosome Development and Manufacturing Services Market in the Upcoming Years.
The Discovery / Research Segment is Expected to Drive the Exosome Development and Manufacturing Services Market. Exosomes' enormous potential in therapeutics and diagnostics, including drug transport and regenerative medicine, can be attributable to this. Within academic and scientific institutes, research activities have surged due to the interest surrounding these prospective uses. Exosomes are being investigated by scientists as potential indicators for a number of diseases and as delivery systems for specific drugs, which is driving an increase in research projects.
Regionally, North America Led The Exosome Development and Manufacturing Services Market In 2023.
North America has a well-established framework for financing R&D projects, offering monetary assistance to businesses engaged in exosome investigation. Furthermore, North America's regulatory framework frequently encourages innovation in the life sciences industry. Many government-funded studies have been carried out to investigate the potential involvement of medications utilizing exosomes in diverse cancer types, including pancreatic cancer, lung cancer, melanoma, and breast cancer.
Exosome Development and Manufacturing Services Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 17.2 Bn |
|
Revenue Forecast In 2031 |
USD 62.8 Bn |
|
Growth Rate CAGR |
CAGR of 17.9% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Types of Service(s) Offered, Scale of Operation, and Scalability |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
101 Bio,10x Genomics, Aegle Therapeutics, Aethlon Medical, AMSBIO, Anjarium Biosciences, Aruna Bio, Bio-Techne,Capricor Therapeutics,CD Bioparticles, Cell Guidance Systems, Cellular Biomedicine Group (CBMG),Clara Biotech,Codiak, BioSciences, Creative Biolabs, Creative Biostructure, Creative Bioarray, Creative ProteomicsCurexsys, Direct Biologics, EV Therapeutics, EVerZom,Evox Therapeutics, ExoCoBio, Exogenus Therapeutics, Exosome Diagnostics, Exosome Plus, Exosomics, Exopharm, Exosome Sciences, Exosome Diagnostics, Exosome Plus, Izon Science, Kimera Labs, Lonza, MDimune, Miltenyi Biotec, NanoView Biosciences, Norgen Biotek, NurExone Biologic, System Biosciences (SBI), Takeda, Thermo Fisher Scientific, Vesigen Therapeutics, VivaZome Therapeutics, XOStem. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
